VIRX.Viracta Therapeutics, INC

10-Q: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sentiment:

Quarterly Report

📋All filings for Viracta Therapeutics, INC
🔒Login to Follow

Viracta Therapeutics reports a net loss of $10.55 million for the third quarter of 2024 and provides an update on its clinical programs, including a strategic shift to focus on lymphoma.

Delay expectedThe company has paused its EBV+ solid tumor program to focus on the EBV+ lymphoma program, indicating a delay in the development of the solid tumor program.The company has experienced delays in site engagement and timely site initiations in the NAVAL-1 trial.
Capital raiseThe company states that it will need to raise additional capital through the issuance of its common stock, through other equity or debt financings or through collaborations or partnerships with other companies, to fund its continued operations.Management believes that its existing cash, cash equivalents and short-term investments may not be sufficient to fund the company's planned operations for at least twelve months from the issuance date of these condensed consolidated financial statements.
Worse than expectedThe company's financial position is weak, with a significant accumulated deficit and a working capital deficit.Management believes that existing cash may not be sufficient to fund operations for the next twelve months.The company has implemented two reductions in force, indicating financial challenges.

Summary

  • Viracta Therapeutics, a clinical-stage oncology company, reported a net loss of $10.55 million for the three months ended September 30, 2024, and a net loss of $29.52 million for the nine months ended September 30, 2024.
  • The company's research and development expenses were $7.18 million for the quarter and $23.69 million for the nine-month period.
  • General and administrative expenses were $3.00 million for the quarter and $9.97 million for the nine-month period.
  • As of September 30, 2024, Viracta had cash, cash equivalents, and short-term investments totaling $21.1 million and a working capital deficit of $6.8 million.
  • The company has paused its EBV+ solid tumor program to focus resources on the more advanced EBV+ lymphoma program.
  • Viracta plans to initiate a randomized controlled trial of Nana-val in the second-line treatment of EBV+ PTCL patients in 2025.
  • The company implemented a reduction in force in July 2024, impacting approximately 23% of its workforce, and another in October 2024, impacting approximately 42% of its workforce.
  • Management believes that existing cash, cash equivalents and short-term investments may not be sufficient to fund planned operations for at least twelve months from the issuance date of the financial statements.

Sentiment

Score: 3

Explanation: The document presents a challenging financial situation with significant losses, a working capital deficit, and a need for additional capital. The strategic shift and workforce reductions, while potentially necessary, add to the negative sentiment. The company's going concern status also contributes to the low score.

Positives

  • The company has received Fast Track Designation by the FDA for the treatment of R/R EBV + lymphoid malignancies.
  • The European Commission has granted orphan drug designation to Nana-val for the treatment of PTCL and DLBCL.
  • Viracta has received orphan drug designations in the United States for the treatment of EBV + DLBCL, not otherwise specified, PTLD, plasmablastic lymphoma, and T-cell lymphoma.
  • The company has completed enrollment in the seventh dose cohort of its Phase 1b/2 trial for EBV+ solid tumors and determined the recommended Phase 2 dose.

Negatives

  • The company has experienced net losses since its inception and has an accumulated deficit of $295.5 million.
  • Viracta has a working capital deficit of $6.8 million as of September 30, 2024.
  • The company's existing cash may not be sufficient to fund operations for the next twelve months.
  • Viracta has paused its EBV+ solid tumor program to focus on the EBV+ lymphoma program.
  • The company has implemented two reductions in force, impacting a total of approximately 65% of its workforce.

Risks

  • The company's ability to continue as a going concern is in doubt due to its current liquidity position and recurring losses.
  • Viracta needs to raise additional capital to fund its operations and may be unable to do so on favorable terms or at all.
  • There are risks associated with the development and commercialization of Nana-val, including clinical trial delays and regulatory hurdles.
  • The company faces significant competition in the biotechnology and pharmaceutical industries.
  • There are risks associated with the company's reliance on third-party manufacturers and contract research organizations.
  • The company is subject to various legal and regulatory risks, including healthcare fraud and abuse laws.
  • The company's stock price is volatile and may be affected by various factors, including market conditions and company-specific news.

Future Outlook

Based on the company's current financial position and business plan, management believes that its existing cash, cash equivalents and short-term investments may not be sufficient to fund the company's planned operations for at least twelve months from the issuance date of these condensed consolidated financial statements. The company plans to initiate a randomized controlled trial of Nana-val in the second-line treatment of EBV+ PTCL patients in 2025.

Management Comments

  • Management believes that its existing cash, cash equivalents and short-term investments may not be sufficient to fund the company's planned operations for at least twelve months from the issuance date of these condensed consolidated financial statements.
  • Management has concluded that its plans do not alleviate substantial doubt about the company's ability to continue as a going concern.

Industry Context

The company is operating in the competitive oncology space, focusing on virus-associated cancers, particularly those related to the Epstein-Barr virus. The strategic shift to focus on lymphoma reflects a prioritization of resources towards a more advanced program.

Comparison to Industry Standards

  • The company's financial position, with a significant accumulated deficit and a working capital deficit, is not uncommon for clinical-stage biotechnology companies.
  • The decision to pause the EBV+ solid tumor program to focus on lymphoma is a strategic move to allocate resources to a more promising area, which is a common practice in the industry.
  • The planned randomized controlled trial of Nana-val in second-line EBV+ PTCL is a standard approach for seeking regulatory approval for cancer therapies.
  • The company's reliance on third-party manufacturers and CROs is typical for companies of its size and stage of development.
  • The company's cash burn rate and need for additional capital are consistent with other companies in the clinical-stage biotechnology sector.

Stakeholder Impact

  • Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional capital.
  • Employees have been impacted by the reductions in force, leading to job losses.
  • Customers (potential patients) may experience delays in the development of new therapies due to the strategic shift and program pause.
  • Suppliers and creditors may face increased risk due to the company's financial challenges.

Next Steps

  • Initiate a randomized controlled trial of Nana-val in the second-line treatment of EBV+ PTCL patients in 2025.
  • Continue the NAVAL-1 trial for EBV+ lymphoma.
  • Seek additional funding through equity or debt financings or through collaborations or partnerships with other companies.

Key Dates

DateDescription
November 29, 2020The Company, then operating as Sunesis Pharmaceuticals, Inc., entered into an agreement and plan of merger and reorganization with privately held Viracta Therapeutics, Inc.
February 24, 2021The transactions contemplated by the Merger Agreement were completed, and Merger Sub merged into Private Viracta.
February 25, 2021The combined company's common stock began trading on The Nasdaq Capital Market under the ticker symbol VIRX.
May 28, 2021The Company entered into an Open Market Sale Agreement with Jefferies LLC.
June 2021Viracta initiated NAVAL-1, a pivotal, global, multicenter, open-label Phase 2 basket trial to evaluate Nana-val for the treatment of patients with R/R EBV + lymphoma.
November 4, 2021The Company entered into a loan and security agreement with Silicon Valley Bank and Oxford Finance LLC.
January 2022Viracta announced the first patient dosed in its multinational, open-label, Phase 1b/2 trial for the treatment of patients with recurrent or metastatic (R/M) EBV + NPC and other EBV + solid tumors.
December 29, 2022The second tranche of $20.0 million was drawn by the Company under the SVB-Oxford Loan Facility.
December 31, 2023The availability of the additional tranche of $25.0 million under the SVB-Oxford Loan Facility expired.
March 1, 2024The Company entered into a Second Amendment under the SVB-Oxford Loan Facility.
March 4, 2024The Company entered into an Amendment No. 1 to the license agreement with Day One to monetize a pre-commercialization, event-based milestone for $5.0 million.
July 2024The Company committed to and implemented a reduction in force, completed in August 2024, that impacted approximately 23 % of the Company's workforce.
August 2024Viracta reported combined Stages 1 and 2 data from the R/R EBV + PTCL cohort of 21 patients in the NAVAL-1 trial and announced it has aligned resources to focus on its more advanced EBV + lymphoma program and will pause the EBV + solid tumor program.
August 21, 2024First Amendment to Lease between Plastino II, LP and Viracta Therapeutics, Inc.
October 2024The Company committed to and implemented an additional reduction in force that impacted approximately 42 % of the Company's workforce.
November 1, 2026The loan under the SVB-Oxford Loan Facility will be due on the scheduled maturity date.

Keywords

Viracta Therapeutics, nanatinostat, valganciclovir, Nana-val, Epstein-Barr virus, EBV, lymphoma, solid tumors, clinical trials, oncology, FDA, orphan drug designation, financial results, research and development, capital raise, going concern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.